Navigation Links
NOTICE OF YM BIOSCIENCES CONFERENCE CALL TO DISCUSS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER
Date:8/5/2008

MISSISSAUGA, ON, Aug. 5 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, will hold a conference call hosted by Mr. David Allan, Chairman and CEO, at 12:00pm EDT today, August 5, where members of the professional investment community are invited to discuss the preliminary results obtained from its open-label, Phase II study (YMB1000-015) of nimotuzumab in patients with irinotecan-refractory, metastatic colorectal cancer (mCRC) with management.

CONFERENCE CALL DETAILS

DATE: August 5, 2008

TIME: 12:00 PM Eastern Time

DIAL IN NUMBER: 416 644 3419 and 1 800 731 5774

A live audio webcast of the conference call will be available at http://www.ymbiosciences.com.

About YM BioSciences

YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. In addition to nimotuzumab, the Company is developing AeroLEF(TM), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF- will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
2. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
3. Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq
4. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
5. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
6. YM BIOSCIENCES NOTICE OF ANNUAL MEETING OF SHAREHOLDERS AND NOMINATION OF DIRECTORS
7. Maxygen Third Quarter 2007 Financial Results Conference Call Notice
8. Notice of Conference Call and Webcast
9. Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market
10. Healthcare Technologies, Ltd. Receives Notice From Nasdaq
11. Tapestry Receives Notice Regarding Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... ... January 12, 2017 , ... After her brain cancer ... gave her only a few months to live. Now a paper publishing January ... Rosendahl’s disease and increased both the quantity and quality of her life: Adding ...
(Date:1/12/2017)... and Pune, India , January 12, 2017 ... Market by Type and End Users - Global Opportunity Analysis and Industry Forecast, 2014-2022," ... 2022 from $2,921 million in 2015, growing at a CAGR of 15.07% during the ... ... Allied Market Research Logo ...
(Date:1/11/2017)... ... January 11, 2017 , ... Phase 1 clinical trial ... of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ breast cancer. The ... percent of these heavily pretreated patients saw clinical benefit from the drug, with ...
(Date:1/11/2017)... ... January 11, 2017 , ... Photonics industry and STEM ... are commending the U.S. Congress and President Obama for their recognition of the ... the American Innovation and Competitiveness Act (AICA). , The language of the act ...
Breaking Biology Technology:
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell ... sensor technology, and STMicroelectronics (NYSE: STM), a ... of electronics applications, announced today the launch of ... for biometric wearables that includes ST,s compact ... Valencell,s Benchmark™ biometric sensor system. Together, SensorTile ...
(Date:12/16/2016)... Research and Markets has announced the addition of the "Biometric ... to their offering. ... The biometric vehicle access system market, in terms of value, ... to 2021. The market is estimated to be USD 442.7 Million ... The growth of the biometric vehicle access system market is fueled ...
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
Breaking Biology News(10 mins):